Swiss regulators have agreed to review Cx601 as a treatment for Crohn’s-disease-related skin sores known as complex perianal fistulas. The Swiss Agency for Therapeutic Products, or Swissmedic, granted orphan drug status to the stem cell therapy in September 2016 — recognition that better treatments are needed for the rare, debilitating condition. The European Medicine Agency’s Committee for Medicinal Products for Human